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Background.To determine clinical proﬁle and management of retinoblastoma among children at Kinshasa in Democratic Republic
of Congo. Patients and methods. The medical records of patients with a diagnosis of retinoblastoma seen at the University Hospital
of Kinshasa from January 1985 till December 2005 were retrospectively reviewed. Demographic proﬁle, clinical data, modes of
treatment and outcome were analysed. Results. A total of 49 children, of whom 40 had adequate data on record were identiﬁed as
retinoblastoma (28 males and 12 females). Nine cases had bilateral disease. The median age at the ﬁrst symptoms was 9 months
(range, 1 month to 6 years) for unilateral retinoblastoma and 18 months (range, 1 month to 3.5 years) for bilateral retinoblastoma.
The median age at the ﬁrst oncology consultation was 2.4 years (range, 6 months to 6 years) for unilateral retinoblastoma and
2.4years (range, 9 months to 4 years) for bilateral disease. Leukokoria was present in 67.5% of subjects. Seventy-ﬁve percent
abandoned the treatment. The mortality was 92.5%. Conclusion. In Democratic Republic of Congo, retinoblastoma remains a life
threatening disease characterized by late referral to a specialized unit and aﬀordability of chemotherapy; all leading to an extension
of the disease and high mortality.
1.Introduction
Retinoblastoma is the most frequent childhood intraocular
tumour with an approximately incidence of one in 15,000–
20,000 births in the world [1]. In Africa, it is the most
important life-threatening ocular malignancy [2–4]. Man-
agement of retinoblastoma has been changing during years
with a survival rate of more than 95% in developed countries
[5, 6]. However, in developing countries these cures are
less than 50%, primarily because of advanced disease at
time of diagnosis [7–9]. Previous studies had reported
epidemiological and clinical characteristics of the disease
[10–12]. In the Democratic Republic of Congo (DRC),
retinoblastoma represents 5/188 of malignant tumors in
children [13], 8% of exophthalmos [14]. In other previous
study, retinoblastoma was the most common histologic form
representing31.7%ofallmalignantoftheeye[15].However,
there is still a paucity of information on clinical ﬁndings and
on the outcomes of children with retinoblastoma. The last
paper on presenting signs of retinoblastoma in Congolese
patients gave a ﬁve-year ophthalmology view [16]. At the
other side, it is necessary for health plan to have the main
characteristics of all children with retinoblastoma followed
in Democratic Republic of Congo. This information will
give the whole view of patients and may serve to rule out
general public health and in-hospital cancer politics in poor
resources settings.
The aim of this study is to present data over two
decades about clinical presentation and outcome of children
with retinoblastoma treated at the University Hospital of2 Journal of Cancer Epidemiology
Table 1: First symptoms in 40 patients with retinoblastoma.
Symptom No. of cases % Laterality
Unilateral Bilateral
Leukocoria 27 67.5 21 6
Proptosis 6 15 5 1
Redness 3 7.5 2 1
Hyphema 2 5 2 —
Strabismus 1 2.5 1 1
Unknown 1 2.5 1 —
Total 40
Kinshasa, which is a referral and tertiary care center in West
of Democratic Republic of Congo and to compare the results
with those reported in the literature.
2. Methods
The medical records of all patients with a diagnosis of
retinoblastoma seen in the Pediatrics Oncology Unit at the
University Teaching Hospital of Kinshasa, between January
1985 and December 2005 were reviewed retrospectively. We
usedhospital-baseddatafromtherecordsbecausethereisno
population-based cancer registry in Democratic Republic of
Congo.
The diagnosis of retinoblastoma was based upon history,
clinicalexaminationatUniversityHospitalofKinshasa.Clin-
ical examination with complete ocular examination includ-
ing dilated ophthalmoscopy under general anaesthesia and
physical examination by a paediatrician was systematically
practiced. Ancillary studies consisted of ocular ultrasonog-
raphy and computed tomography when aﬀordable, which
showed the presence of solid intraocular tumor with calcium
deposits. The data collected included demographics features,
reference, order among siblings, the initial sign noticed by
the family, age at ﬁrst symptom, clinical ﬁndings, age at
diagnosis, laterality, diﬀerent time lag, treatment modalities,
treatment adherence, and outcome. Age at ﬁrst sign means
the age of the child when families noticed for the ﬁrst time
the abnormality (alarming sign). The clinical presentation
report to what the physician had seen when examining the
patient at our institution. Diﬀerent lag times include four
latency periods: (1) the time from the ﬁrst sign to a referral
service, (2) the time from the reference to the pediatrics
oncology unit, (3) the time from pediatrics consultation to
the initiation of treatment, and (4) the observational time
from treatment (followup). We divided the study period in
two parts considering the year 1998 as the limitation. After
that year, the treatment had been systematised with at least
3 drugs. Chemoreduction regimen consisted in Vincristine,
Adriamycin, Cyclophosphamide for a maximum of six cycles
given every 3 weeks before and after enucleation) following
the International Conference on Paediatric Oncology in
Morocco in 1998 (http://www.smhop.org.ma/).
Statistical analysis was performed using the statistics
software SPSS for windows (15.0 SPSS, Chicago). Data are
represented as means±SD when the distribution was normal
Table 2: Presenting signs in 40 patients with retinoblastoma.
Presenting sign No. of cases % Laterality
Unilateral Bilateral
Proptosis 22 55 18 4
Leukokoria 10 25 6 4
Strabismus 4 10 3 1
Mass 4 10 3 1
Uveitis 3 7,5 2 1
Buphtalmos 3 5 2 1
Hyph´ ema 3 5 3 —
Convulsions 1 2.5 1 —
and median with range when the distribution was not
normal.
3. Results
A total of 49 children were identiﬁed as retinoblastoma
duringthestudyperiod.Nineofthemwereexcludedbecause
ofinsuﬃcientinformation,anddataof40patients,including
28 males (70%) and 12 females (30%) were reviewed. We
observed a male/female ratio of 2.3:1. Our patients were
referred from the ophthalmology unit of the hospital (33
cases82.5%)andothercentres(7cases17.5%).Theirmedian
order among siblings was 4 (range 1 to 10). During the
study period, 31 cases (77.5%) had unilateral disease [16
cases (40%) left and 15 cases (37.5%) right] and 9 cases
(22.5%) had bilateral disease, resulting in 49 aﬀected eyes.
In unilateral retinoblastoma, there were 20 boys and 11
girls with sex ratio 2:1. In bilateral disease, there were 8
boys and 1 girl with sex ratio 8:1. The median age at
the ﬁrst sign noticed by families was 1.9 years (range one
month to six years) for unilateral disease and 1.4 year (range
one month to three years and half) for bilateral disease
while the median age of the diagnosis in our institution
was 2.8 years (range six months to six years) for unilateral
disease and 2.4 years (range nine months to four years)
for bilateral disease. None of the parents of the patients
studied had previous child with retinoblastoma. Leukokoria
(n = 27) and proptosis (n = 6) were the most frequent
initial signs noticed by families (Table 1). At diagnosis in
our institution (Table 2), the most frequent clinical ﬁndings
were proptosis (n = 22) and leukokoria (n = 10). Four
delaying time are listed. A median 9 months (range, 1 to 79
months) passed from detection of the ﬁrst sign to referral
(lag time), 1 month (range, 0 to 23 months) from referral
to paediatric oncology unit, 9.5 months (range, 0 months
to 3.3 years) from paediatric consultation to treatment,
and 2.3 months (range, 0 to 18 moths) from treatment
initiation to last followup. An average of 15 months passed
between the detection of the ﬁrst sign and the beginning
of therapy if applied. At diagnosis, 36 (90%) patients had
stage 4 of the Reese-Ellsworth classiﬁcation. Four patients
had localized disease, twenty six had locoregional disease,
andten hadmetastaticdisease. Thesitesofmetastaticdisease
were brain (n = 4), lymph nodes (n = 3), bone (n = 2),Journal of Cancer Epidemiology 3
Table 3: Regimens, courses, duration, and followup of chemotherapy for retinoblastoma over time.
Regimen Years n Mean n◦ of chemotherapy courses (ranges) Followup from start of treatment (months)
C/wk 1995–1990 8 3.6 (2–6) 1
VC-enu-VC 1991 1 12 9
VC/wk 1991–1996 8 5.5 (5–6) 3
VC-Prednisolone 1992 1 1 21 days
VC-VAC+M 1996 2 24.5 (6-43) 10
VAC+M/3 wks 1997–2000 4 5.25 (1–12) 5
VAC/3wks 1998–2005 14 3.1 (1–6) 6
VMC-VAC-enu- 2003 1 16 15
VAC+VMC/3wk 2004 1 1 13
C: cyclophosphamide; V: vincristine; A: Adriamycine; M: methotrexate; enu: enucleation.
Table 4: Characteristics of 7 patients who died of retinoblastoma.
N◦ Age (months) Sex Years Regimen Chemotherapy course Followup (months) Laterality
1 44 M 1986 C 3 1.3 Unit
2 41 F 1990 C 5 2.3 Unit
3 29 M 1996 VCVACMTX 6 3.5 Unit
4 15 F 1996 VCVACMTX 43 17 Unit
5 80 M 1996 VC 5 3.5 Unit
6 27 F 2004 VAC 3 4 Unit
7 42 M 2005 VAC 0 1 Unit
C: cyclophosphamide; V: vincristine; A: Adriamycine; M: methotrexate.
and bone marrow (n = 1). From 1985 to 1998, 23 patients
(57.5%) have been treated and 17 (42.5%) from 1998 to the
2005. Diﬀerent chemotherapy regimens had been used. No
local conservative treatment was applied. The Table 3 shows
chemotherapy protocols to be used and those eﬀectively
applied to patients.
The outcomes of our patients were as follows: 30 (75%)
children were lost from followup, 7 (17.5%) died among
which 5 had proptosis with an orbital extension, 2 had pro-
truded mass development after enucleation (characteristics
presented in Table 4), one was referred abroad for treatment,
and two were alive at the time of ﬁnal data entry. Assuming
that cases lost to followup worsened and died, the mortality
would be 92.5%.
4. Discussion
Our study is the ﬁrst to look at the outcome and the
limitations to management of retinoblastoma in Democratic
Republic of Congo. The study spanned 20 years and 49
cases of retinoblastoma were identiﬁed during that time.
From mid 1998 to 2005, 17 patients were identiﬁed. This
is an extremely small number. The calculation based on
incidence of retinoblastoma in Africa, data from Index
Mundi available for 2005 (http://www.indexmundi.com/g/g
.aspx?c=cg&v=25/), and estimate population in 1999, we can
giveanestimateoincidenceofretinoblastomainDemocratic
Republic of Congo approximately of 976–1098 cases and the
the total number of children in this study indicates that only
a tiny fraction of Congolese children with retinoblastoma
beneﬁted from treatment in our tertiary referral center. It
is common for some children with retinoblastoma to be
taken to herbalist or prayer houses instead of hospital. This
situation is due to cultural beliefs, stigma, and ignorance
[17, 18]. The male-female ratio in our study is 2.3:1. Many
authors reported similar observations [14, 16, 19, 20], but in
others the occurrence of retinoblastoma is almost the same
in both sexes [11, 21, 22]. The fact of sex ratio in the present
study had been reported to be related to environmental
f a c t o r so rt ob i a sr e f e r r a l .
The main referral to paediatric oncology was the oph-
thalmology unit of our institution with 82.5% of patients.
In a previous study from the Ophthalmology Unit of
the University Hospital of Kinshasa, half of patients are
referred by surroundings ophthalmologists [16]. This may
be explained by some obstacles outside University Hospital
of Kinshasa as lack of paediatrician and ophthalmologist.
In-hospital reference from ophthalmologist to paediatrician
could help in the early management because it was reported
in Argentina that the paediatrician underestimated the
complaints in half patients while the diagnosis was suspected
by the ophthalmologist on the ﬁrst visit [23].
The frequency of bilateral disease of retinoblastoma
was 22.5% of patients. This frequency varies from 10 to
50% in diﬀerent studies [1, 19, 24–26]. It might be that
some bilateral cases are lost to followup before second
eye involvement appears, leading to misclassiﬁcation as
unilateral in our context.
The age at diagnosis of retinoblastoma in developing
countries varies from 24 months to 3 years [16, 24, 27, 28].
In this study, the age of our patients ranged from 6 months4 Journal of Cancer Epidemiology
to 6.6 years and averaged 32 months. The mean age when
ﬁrst sign had noticed by parents was 20, 4 months, meaning
a year average lost of time before reaching a hospital due to
lake of information, education, or poor socioeconomic level.
Diﬀerent studies reported similar observations in developing
countries [12, 20, 24, 28]. Leukokoria (67.5%) had been
the ﬁrst sign noticed by parents. In medical consultation,
proptosis and leukokoria were the most common clinical
presentation, similar to that from other developing countries
[4, 20, 23, 26, 28, 29]. Computer tomography is generally
avoided in bilateral retinoblastoma because radiation may
increase risk of second cancers. The use of computer
tomography in our study reﬂects scarce magnetic reso-
nance imaging resources. The diagnosis or presentation of
retinoblastoma in Kinshasa is delayed. Similar observations
were reported in other studies in developing countries [20,
23,26,30].Thepredominanceofproptosisisduetothedelay
in consultation and the development of the tumour because
there is a link between the lag time and the expansion of
the tumour [31]. However, in other settings leukokoria still
remains the presenting sign at the hospital [32, 33]. Another
explanation rises as been reported from the use of self-
treatments or traditional healers’ treatments before reaching
a hospital or during the period between a health centre and
the pediatrics oncology unit [34, 35]. So, retinoblastoma is
diagnosed late with extraocular dissemination, and there is
tremendous scope for improvement in its managements as
performed in developed countries [20]. This should lead to
set up an informational program for careful screening and
referral of “white pupil” for early diagnosis and treatment as
proposed elsewhere [36, 37].
ThechemotherapyofretinoblastomainKinshasaevolved
from one drug to a 3 drugs combination therapy every 3
weeks during the study period. The Chemotherapy regimen
(Vincristine; Adriamycine Cyclophosphamide) had been
systematically applied since 1998. Chemotherapy was not
given regularly according to established standard treatment
guidelines. The major reason for this is resource deﬁciency.
Most of the parents of our patients are poor and because a
free health care facility is not available in most developing
countries, these drugs are not aﬀordable to many of the
patients. An additional factor is the unavailability and high
cost of some drugs in Democratic Republic of Congo. This
situation contributes to lack of treatment adherence and
patients being lost to followup. In our series, the number
o ft r e a t m e n ta b a n d o n m e n ta n dl o s to ff o l l o w u pi sh i g h .
This high treatment abandonment may be the result of late
presentation as well as poor compliance with chemotherapy
regimen. Treatment abandonment as well as loss to followup
has also been reported from other developing countries
[20, 24, 30]. We think that it derives from complex fac-
tors such as ignorance, poverty without health insurance
system, ﬁnancial constraint regarding investigations and
procurement of drugs, lack infrastructure resources, poor
communication between medical teams and patients, and
deep lack of ﬁnancial and infrastructure resources. In our
study, limited management for above reasons and lack of
an accurate tracing system are factors predicting a worse
prognosis.
During these 2 decades, retinoblastoma remains a life-
threatening disease in Democratic Republic of Congo char-
acterized by advanced intraocular disease, late referral to a
specialized unit, delay in treatment, important lost to fol-
lowup, and aﬀordability of chemotherapy. Early educational
detection program, prompt referral to specialized centers,
use of current methods treatment, and an implementation
of a health insurance system particularly for cancers will
improve outcomes for children with retinoblastoma in our
settings.
Acknowledgments
The authors would like to appreciate all students and nurses
of the Paediatric Oncology Unit of the University Hospital of
Kinshasa for their assistance in collecting the data.
References
[1] J.A.ShieldsandC.L.Shields,“Retinoblastoma,”inIntraocular
Tumors- A Text and Atlas, C. L. Shields and J. A. Shields, Eds.,
pp. 294–318, Lippincott Williams and Wilkins, Philadeplhia,
Pa, USA, 2nd edition, 2007.
[2] T. Kivel¨ a, “The epidemiological challenge of the most frequent
eyecancer:retinoblastoma,anissueofbirthanddeath,”British
Journal of Ophthalmology, vol. 93, no. 9, pp. 1129–1131, 2009.
[3] A. S. Ka, P. Imbert, C. Moreira et al., “Epidemiology and
prognosis of childhood cancer in Dakar, Senegal,” Medecine
Tropicale, vol. 63, no. 4-5, pp. 521–526, 2003.
[4] J. Freedman and L. Goldberg, “Incidence of retinoblastoma in
the Bantu of South Africa,” British Journal of Ophthalmology,
vol. 60, no. 9, pp. 655–656, 1976.
[5] E. L. Berman, C. E. Donaldson, M. Giblin, and F. J. Martin,
“Outcomesinretinoblastoma,1974–2005:theChildren’sHos-
pital, Westmead,” Clinical and Experimental Ophthalmology,
vol. 35, no. 1, pp. 5–12, 2007.
[6] A.M acCarth y ,J .M.Birch,G.J .Draperetal.,“R etinoblastoma:
treatment and survival in Great Britain 1963 to 2002,” British
Journal of Ophthalmology, vol. 93, no. 1, pp. 38–39, 2009.
[7] R. J. C. Bowman, M. Mafwiri, P. Luthert, J. Luande, and M.
Wood, “Outcome of retinoblastoma in east Africa,” Pediatric
Blood and Cancer, vol. 50, no. 1, pp. 160–162, 2008.
[8] Y. Bhurgri, S. Muzaﬀar, R. Ahmed et al., “Retinoblastoma in
Karachi, Pakistan,” Asian Paciﬁc Journal of Cancer Prevention,
vol. 5, no. 2, pp. 159–163, 2004.
[9] B. De Camargo, M. De Oliveira Santos, M. S. Rebelo et
al., “Cancer incidence among children and adolescents in
Brazil: ﬁrst report of 14 population-based cancer registries,”
International Journal of Cancer, vol. 126, no. 3, pp. 715–720,
2010.
[10] C. P. Yang, I. J. Hung, T. H. Jaing, and W. H. Chang, “Cancers
in the infancy: percent distribution and incidence rates,” Acta
Paediatrica Taiwanica, vol. 47, no. 6, pp. 273–277, 2006.
[11] R. Saiju, J. Thakur, P. C. Karmacharya, and D. N. Shah,
“Retinoblastoma in Nepal: a clinical proﬁle of 30 cases,” Nepal
Medical College Journal, vol. 8, no. 3, pp. 171–175, 2006.
[12] H. Ozdemir, N. Tacyildiz, E. Unal, G. Yavuz, H. Ugur, and
K. Gunduz, “Clinical and epidemiological characteristics of
retinoblastoma: correlation with prognosis in a Turkish Pedi-
atric Oncology Center,” Pediatric Hematology and Oncology,
vol. 24, no. 3, pp. 221–231, 2007.Journal of Cancer Epidemiology 5
[13] P. R. Fischer, L. O. Ahuka, P. B. Wood, and S. Lucas, “Malig-
nant tumors in children of northeastern Zaire: a comparison
of distribution patterns,” Clinical Pediatrics,v o l .2 9 ,n o .2 ,p p .
95–98, 1990.
[14] D. K. Kaimbo, J. Kilangalanga, and L. Missoten, “Exoph-
thalmias in zaire,” Bulletin de la Soci´ et´ e Belge d’Ophtalmologie,
vol. 259, pp. 199–204, 1995.
[ 1 5 ]M .Y .P o s o ,J .C .K .M w a n z a ,a n dD .L .K a y e m b e ,“ M a l i g n a n t
tumors of the eye and adnexa in Congo-Kinshasa,” Journal
Francais d’Ophtalmologie, vol. 23, no. 4, pp. 327–332, 2000.
[16] W. K. Kaimbo, M. M. Mvitu, and L. Missotten, “Presenting
signs of retinoblastoma in Congolese patients,” Bulletin de la
Societe Belge d’Ophtalmologie, no. 283, pp. 37–41, 2002.
[17] T. Mambu Nyangi Mondo, M. Malengreau, P. Kayembe
Kalambayi,andB.L.Dimomfu,“Delaysinseekingandgetting
care, in seriously ill women of childbearing age in Kinshasa,”
Revue d’Epidemiologie et de Sante Publique,v o l .5 8 ,n o .3 ,p p .
189–196, 2010.
[18] L. P. Sabuni, “Dilemma with the local perception of causes
of illnesses in central Africa: muted concept but prevalent in
everyday life,” Qualitative Health Research, vol. 17, no. 9, pp.
1280–1291, 2007.
[19] L. Kayembe, “Retinoblastoma: review of a 21 year follow-up,”
Journal Francais d’Ophtalmologie, vol. 9, no. 8-9, pp. 561–565,
1986.
[ 2 0 ]C .O .B e k i b e l e ,A .I .A y e d e ,O .O .A s a o l u ,a n dB .J .B r o w n ,
“Retinoblastoma: the challenges of management in Ibadan,
Nigeria,” JournalofPediatricHematology/Oncology,vol.31,no.
8, pp. 552–555, 2009.
[21] J. F. Owoeye, E. A. Afolayan, and D. S. Ademola-Popoola,
“Retinoblastoma—a clinico-pathological study in Ilorin,
Nigeria,” African Journal of Health Sciences, vol. 13, no. 1-2,
pp. 117–123, 2006.
[22] T. Mouratova, “Retinoblastoma in Uzbekistan,” Bulletin de la
Societe Belge d’Ophtalmologie, no. 289, pp. 63–69, 2003.
[23] G. Chantada, A. Fandi˜ no, J. Manzitti, L. Urrutia, and E.
Schvartzman, “Late diagnosis of retinoblastoma in a develop-
ing country,” Archives of Disease in Childhood, vol. 80, no. 2,
pp. 171–174, 1999.
[24] A. A. E. Ali, S. M. A. Elsheikh, A. Elhaj et al., “Clinical
presentation and outcome of retinoblastoma among children
treated at the National Cancer Institute (NCI) in Gezira,
Sudan: a single institution experience,” Ophthalmic Genetics,
vol. 32, no. 2, pp. 122–125, 2011.
[25] M.P.Shanmugam,J.Biswas,L.Gopal,T.Sharma,andS.H.M.
Nizamuddin, “The clinical spectrum and treatment outcome
of retinoblastoma in Indian children,” Journal of Pediatric
Ophthalmology and Strabismus, vol. 42, no. 2, pp. 75–113,
2005.
[26] B. Badhu, S. P. Sah, S. K. D. Thakur et al., “Clinical
presentation of retinoblastoma in Eastern Nepal,” Clinical and
ExperimentalOphthalmology,vol.33,no.4,pp.386–389,2005.
[27] I. Alnawaiseh, I. Jaradat, Y. A. Yousef et al., “Retinoblastoma
in Jordan: an epidemiological study (2006–2010),” Hematol-
ogy/OncologyandStemC ellTher apy,vol.4,no.3,pp.126–131,
2011.
[28] V. Essuman, C. T. Ntim-Amponsah, S. Akafo, L. Renner, and
L. Edusei, “Presentation of retinoblastoma at eye clinic in
Ghana,”GhanaMedicalJournal,vol.44,no.1,pp.10–15,2010.
[29] T. Boubacar, S. Fatou, T. Fousseyni et al., “Thirty months
prospective study on the treatment of retinoblastoma in
Gabriel Tour´ e Bamako Mali: 55 cases,” British Journal of
Ophthalmology, vol. 94, no. 4, pp. 467–469, 2010.
[30] A. U. Mukhtar and K. Kagame, “Pathological study of
retinoblastoma in Mbarara, Uganda,” Central African Journal
of Medicine, vol. 46, no. 1, pp. 13–16, 2000.
[31] C. B. Antoneli, F. Steinhorst, K. C. Ribeiro et al., “The
Pediatrician’s ability to recognize the presenting signs and
symptoms of retinoblastoma,” Revista da Associac ¸˜ ao M´ edica
Brasileira, vol. 50, no. 4, pp. 400–402, 2004.
[32] B. S. Menon, J. Alagaratnam, E. Juraida, M. Mohamed, H.
Ibrahim, and N. N. Nyi, “Late presentation of retinoblastoma
in Malaysia,” Pediatric Blood and Cancer,v o l .5 2 ,n o .2 ,p p .
215–217, 2009.
[33] C. Y. Chang, T. J. Chiou, B. Hwang, L. Y. Bai, W. M. Hsu,
and Y. L. Hsieh, “Retinoblastoma in Taiwan: survival rate and
prognosticfactors,”JapaneseJournalofOphthalmology,vol.50,
no. 3, pp. 242–249, 2006.
[34] J. Mselle, “Visual impact of using traditional medicine on the
injured eye in Africa,” Acta Tropica, vol. 70, no. 2, pp. 185–192,
1998.
[35] J. C. K. Mwanza, “Corneal complications of local ocular
traditional treatment in the Democratic Republic of Congo,”
Medecine Tropicale, vol. 61, no. 6, pp. 500–502, 2001.
[36] S. O. Ekenze, H. Ekwunife, B. I. Eze, A. Ikefuna, C. C. Amah,
and I. J. Emodi, “The burden of pediatric malignant solid
tumors in a developing country,” Journal of Tropical Pediatrics,
vol. 56, no. 2, pp. 111–114, 2009.
[37] C. Leander, L. C. Fu, A. Pe˜ na et al., “Impact of an education
program on late diagnosis of retinoblastoma in Honduras,”
Pediatric Blood and Cancer, vol. 49, no. 6, pp. 817–819, 2007.